JP2024010026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024010026A5 JP2024010026A5 JP2023180119A JP2023180119A JP2024010026A5 JP 2024010026 A5 JP2024010026 A5 JP 2024010026A5 JP 2023180119 A JP2023180119 A JP 2023180119A JP 2023180119 A JP2023180119 A JP 2023180119A JP 2024010026 A5 JP2024010026 A5 JP 2024010026A5
- Authority
- JP
- Japan
- Prior art keywords
- etanercept
- pharmaceutical composition
- polysorbate
- excipients
- concentrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010008165 Etanercept Proteins 0.000 claims 8
- 229960000403 etanercept Drugs 0.000 claims 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001219 Polysorbate 40 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960005337 lysine hydrochloride Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- -1 polyoxyethylene copolymers Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940101027 polysorbate 40 Drugs 0.000 claims 1
- 229940113124 polysorbate 60 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 229960001153 serine Drugs 0.000 claims 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Claims (8)
- 40mg/mL~100mg/mLのエタネルセプト、及び2.0mM未満の全添加緩衝剤を含み、6.1~6.5の標的pHであるエタネルセプトの医薬組成物を製造する方法であって、
pH6.1~6.6のエタネルセプトの緩衝製剤を、pH5.6~6.5の非緩衝製剤に交換するステップと、
前記エタネルセプトを40mg/mL~100mg/mLに濃縮するステップと
を含む、方法。 - エタネルセプトの緩衝製剤中のエタネルセプトを、40mg/mL~100mg/mLに濃縮するステップを含む、請求項1に記載の方法。
- 40mg/mL~100mg/mLに交換した後、得られた組成物中のエタネルセプトを濃縮するステップを含む、請求項1に記載の方法。
- 医薬組成物が、75mM~150mMのNaCl、5mM~100mMのアルギニン、及び0.5%~2.5%(w/v)のスクロースを含む、請求項1~3のいずれか一項に記載の方法。
- 5mM~100mMのアルギニン、40mg/mL~100mg/mLのエタネルセプト、一以上の賦形剤を含む医薬組成物であって、2.0mM未満の全添加緩衝剤を含み、等張であり、組成物のpHが6.1~6.5である、医薬組成物。
- 一以上の賦形剤が、糖/ポリオール、ポリマー、非水性溶媒、アミノ酸、及び/又は界面活性剤の一以上から選択される、請求項5に記載の医薬組成物。
- 一以上の賦形剤が、スクロース、ラクトース、グリセロール、キシリトール、ソルビトール、マンニトール、マルトース、イノシトール、トレハロース、及び/又はグルコースから選択される糖/ポリオール;血清アルブミン、デキストラン、PVA、ヒドロキシプロピルメチルセルロース(HPMC)、ポリエチレンイミン、ゼラチン、ポリビニルピロリドン(PVP)、及び/又はヒドロキシエチルセルロース(HEC)から選択されるポリマー;PEG、エチレングリコール、グリセロール、ジメチルスルホキシド(DMSO)、及び/又はジメチルホルムアミド(DMF)から選択される非水性溶媒;プロリン、L-セリン、アラニン、グリシン、塩酸リシン、サルコシン、及び/又はガンマ-アミノ酪酸から選択されるアミノ酸;並びに/又は、ポリソルベート20、ポリソルベート40、ポリソルベート60、及びポリソルベート80、ドデシル硫酸ナトリウム(SDS)、ポリオキシエチレンコポリマー、ポロキソマー188、ポロキソマー407、CHAPS、及び/又はモノラウレートから選択される界面活性剤を含む、請求項6に記載の医薬組成物。
- 一以上の賦形剤が、NaCl及び/又はスクロースを含む、請求項5に記載の医薬組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662411458P | 2016-10-21 | 2016-10-21 | |
US62/411,458 | 2016-10-21 | ||
JP2019520794A JP6884858B2 (ja) | 2016-10-21 | 2017-10-19 | 医薬製剤及びその製造方法 |
JP2021080160A JP7402195B2 (ja) | 2016-10-21 | 2021-05-11 | 医薬製剤及びその製造方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021080160A Division JP7402195B2 (ja) | 2016-10-21 | 2021-05-11 | 医薬製剤及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2024010026A JP2024010026A (ja) | 2024-01-23 |
JP2024010026A5 true JP2024010026A5 (ja) | 2024-04-24 |
Family
ID=61971152
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019520794A Active JP6884858B2 (ja) | 2016-10-21 | 2017-10-19 | 医薬製剤及びその製造方法 |
JP2021080160A Active JP7402195B2 (ja) | 2016-10-21 | 2021-05-11 | 医薬製剤及びその製造方法 |
JP2023180119A Pending JP2024010026A (ja) | 2016-10-21 | 2023-10-19 | 医薬製剤及びその製造方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019520794A Active JP6884858B2 (ja) | 2016-10-21 | 2017-10-19 | 医薬製剤及びその製造方法 |
JP2021080160A Active JP7402195B2 (ja) | 2016-10-21 | 2021-05-11 | 医薬製剤及びその製造方法 |
Country Status (14)
Country | Link |
---|---|
US (4) | US20180110856A1 (ja) |
EP (1) | EP3528787A4 (ja) |
JP (3) | JP6884858B2 (ja) |
KR (2) | KR102413592B1 (ja) |
CN (2) | CN109982685B (ja) |
AU (1) | AU2017345490B2 (ja) |
BR (1) | BR112019007858A2 (ja) |
CA (1) | CA3040899A1 (ja) |
CL (1) | CL2019001053A1 (ja) |
EA (1) | EA201990998A1 (ja) |
IL (1) | IL266132B (ja) |
MX (1) | MX2019004580A (ja) |
SG (1) | SG11201903521XA (ja) |
WO (1) | WO2018075818A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
JP6884858B2 (ja) * | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
EP4007164A4 (en) | 2020-05-12 | 2022-11-23 | NEC Corporation | DISTORTION COMPENSATION DEVICE AND DISTORTION COMPENSATION METHOD |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2837168A1 (de) | 1978-08-25 | 1980-03-06 | Blutspendedienst Dt Rote Kreuz | Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten immunglobulinloesung |
US4362661A (en) | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
CA1153695A (en) | 1979-08-30 | 1983-09-13 | Syoji Ono | S-sulfonated immunoglobulin composition having a high monomer content and a process for production thereof |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4396608A (en) | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
US5702699A (en) | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
US4681713A (en) | 1984-03-15 | 1987-07-21 | Toyo Boseki Kabushiki Kaisha | Method of making a hollow fiber membrane for dialysis |
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US6673347B1 (en) | 1986-04-30 | 2004-01-06 | Gryphon Therapeutics | Polypeptide and protein derivatives and process for their preparation |
GB8628104D0 (en) | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
DE3640513A1 (de) | 1986-11-27 | 1988-06-09 | Biotest Pharma Gmbh | Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates |
JP2547556B2 (ja) | 1987-02-06 | 1996-10-23 | 株式会社 ミドリ十字 | r−グロブリンの液状製剤 |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
DE3939346A1 (de) | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
GB9017002D0 (en) | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
JP3179538B2 (ja) | 1990-12-11 | 2001-06-25 | ノバルティス アクチエンゲゼルシャフト | 安定なヒトカルシトニンの水性溶液 |
US5110910A (en) | 1991-03-25 | 1992-05-05 | Miles Inc. | Virucidal euglobulin precipitation |
US5256571A (en) | 1991-05-01 | 1993-10-26 | Cytyc Corporation | Cell preservative solution |
AU3095892A (en) | 1991-12-20 | 1993-07-28 | Protein Design Labs, Inc. | Human type antibody reactive with GPIIb/IIIa |
US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
GB9401448D0 (en) | 1994-01-26 | 1994-03-23 | Ciba Geigy Ag | Stable dry powders |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
JP2000515857A (ja) | 1996-07-18 | 2000-11-28 | シーエスエル リミテッド | 免疫グロブリン溶液の低温殺菌 |
TW491855B (en) | 1996-08-07 | 2002-06-21 | Csl Ltd | Purification of immunoglobulins |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
JP3679406B2 (ja) | 1998-05-20 | 2005-08-03 | 協和醗酵工業株式会社 | 遺伝子組換え抗体 |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
DK2270044T3 (en) | 1998-06-09 | 2015-01-26 | Csl Behring Ag | Liquid immunoglobulin G (IgG) product |
US6610206B1 (en) | 1998-10-20 | 2003-08-26 | Advanced Renal Technologies | Buffered compositions for dialysis |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
CA2640956C (en) | 1999-02-03 | 2012-07-03 | Amgen Inc. | B7rp-1 polypeptides |
JP4360758B2 (ja) | 1999-04-08 | 2009-11-11 | ジェネンテック・インコーポレーテッド | 逆の電荷のポリペプチド類をベースにした組成物 |
RU2225221C2 (ru) | 1999-04-09 | 2004-03-10 | Орто-Макнейл Фармасьютикал, Инк. | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина |
EP1171148A2 (en) | 1999-04-19 | 2002-01-16 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
BR0014486A (pt) | 1999-10-04 | 2002-09-17 | Chiron Corp | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado |
DE60039783D1 (de) | 1999-12-14 | 2008-09-18 | Genentech Inc | Lfa-1 antagonisten und tnf-alpha antagonisten zur |
CA2394536A1 (en) | 1999-12-16 | 2001-06-21 | Amgen Inc. | Tnfr/opg-like molecules and uses thereof |
WO2001058473A1 (en) | 2000-02-10 | 2001-08-16 | Wyeth | Method of treating or inhibiting cellular injury or cell death |
DE60028830T2 (de) | 2000-02-16 | 2007-01-18 | Genentech, Inc., South San Francisco | Anti-april antikörper und hybridomazellen |
AU2002224555A1 (en) | 2000-07-25 | 2002-02-05 | Takeda Chemical Industries Ltd. | Process for producing recombinant protein |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
AR031924A1 (es) | 2000-12-14 | 2003-10-08 | Fujisawa Pharmaceutical Co | Anticuerpos anti-cd28 silenciados y el uso de estos |
US6693173B2 (en) | 2000-12-26 | 2004-02-17 | Alpha Therapeutic Corporation | Method to remove citrate and aluminum from proteins |
EE05724B1 (et) | 2001-01-05 | 2014-10-15 | Pfizer Inc. | Antikehad insuliinitaolise kasvufaktori I retseptorile |
ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
US7157557B2 (en) | 2001-02-23 | 2007-01-02 | Immunex Corporation | Increased recovery of active proteins |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
JP2004521474A (ja) | 2001-06-25 | 2004-07-15 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 高圧ガス放電ランプおよび高圧ガス放電ランプの製造方法 |
DE60235989D1 (de) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
PT1425389E (pt) | 2001-08-23 | 2012-02-07 | Genmab As | Anticorpos humanos específicos para interleucina 15 (il-15) |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
JP2005527474A (ja) | 2001-09-20 | 2005-09-15 | コーネル リサーチ ファンデーション インコーポレーテッド | 前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物 |
CN1292655C (zh) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
AU2002359495A1 (en) | 2001-11-30 | 2003-06-17 | Centocor, Inc. | Anti-tnf antibodies, compositions, methods and uses |
WO2003059935A2 (en) | 2001-12-21 | 2003-07-24 | Immunex Corporation | Methods for purifying protein |
DK1475101T3 (da) | 2002-02-14 | 2011-01-10 | Chugai Pharmaceutical Co Ltd | Antistof-holdige farmaceutiske opløsninger |
WO2003072736A2 (en) | 2002-02-21 | 2003-09-04 | Duke University | Reagents and treatment methods for autoimmune diseases |
JP4583762B2 (ja) | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | ポリペプチド製剤 |
JP2005521401A (ja) | 2002-03-27 | 2005-07-21 | イミュネックス・コーポレーション | ポリペプチド産生を増加させる方法 |
PL375041A1 (en) | 2002-04-05 | 2005-11-14 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
WO2003102132A2 (en) | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
NZ537687A (en) | 2002-06-21 | 2008-04-30 | Biogen Idec Inc | Buffered formulations for concentrating antibodies and methods of use thereof |
CA2493067A1 (en) | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | Treatment of tnf.alpha. related disorders |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
JP4500683B2 (ja) | 2002-11-01 | 2010-07-14 | バイエル・ヘルスケア・エルエルシー | 巨大分子濃縮方法 |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
PT1581649E (pt) | 2002-12-20 | 2011-04-13 | Amgen Inc | Agentes de ligação que inibem a miostatina |
WO2004083248A1 (en) | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
US7456147B2 (en) | 2003-05-14 | 2008-11-25 | Dow Corning, Corporation | Controlled release of active agents utilizing repeat sequence protein polymers |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
UA93653C2 (ru) | 2003-11-07 | 2011-03-10 | Иммунекс Корпорейшн | Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r) |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
CA2555791A1 (en) | 2004-02-12 | 2005-08-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Highly concentrated liquid formulations of anti-egfr antibodies |
WO2005095454A1 (en) | 2004-03-25 | 2005-10-13 | Diadexus, Inc. | Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk |
US8333995B2 (en) | 2004-05-12 | 2012-12-18 | Baxter International, Inc. | Protein microspheres having injectable properties at high concentrations |
JPWO2006003999A1 (ja) | 2004-07-05 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗ヒトb7rp−1抗体およびその抗体フラグメント |
US7648742B2 (en) * | 2004-07-29 | 2010-01-19 | Merck Patent Gmbh | Difluorosubstituted heterocyclic compounds and the use thereof in the form of components in liquid crystalline media |
TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
KR20070072510A (ko) | 2004-08-30 | 2007-07-04 | 론자 바이올로직스 피엘씨 | 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피 |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2006064373A2 (en) | 2004-12-16 | 2006-06-22 | Genzyme Polyclonals S.A.S. | Methods of purifying immunologlobulins |
JP4498939B2 (ja) | 2005-02-01 | 2010-07-07 | 東京応化工業株式会社 | ポジ型レジスト組成物およびレジストパターン形成方法 |
US8597709B2 (en) | 2005-04-12 | 2013-12-03 | Inovobiologic Inc. | Dietary supplement and methods of use |
SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070049732A1 (en) | 2005-09-01 | 2007-03-01 | Zurlo Eugene J | Ultra-high yield intravenous immune globulin preparation |
CA2630606A1 (en) | 2005-09-21 | 2007-03-29 | Burcon Nutrascience (Mb) Corp. | Preparation of canola protein isolate involving isoelectric precipitation |
US8067350B2 (en) | 2005-12-15 | 2011-11-29 | Kimberly-Clark Worldwide, Inc. | Color changing cleansing composition |
US20070202051A1 (en) | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
WO2007124082A2 (en) | 2006-04-21 | 2007-11-01 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
CA2663416A1 (en) | 2006-09-15 | 2008-03-20 | Barofold, Inc. | High pressure treatment of proteins for reduced immunogenicity |
ES2442258T3 (es) | 2006-10-27 | 2014-02-10 | Abbvie Biotechnology Ltd | Anticuerpos cristalinos anti-hTNF alfa |
JP5577098B2 (ja) | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
NZ622583A (en) * | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
BRPI0908361A2 (pt) * | 2008-02-07 | 2015-04-07 | Amgen Inc | Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição. |
US8052645B2 (en) | 2008-07-23 | 2011-11-08 | Avant Medical Corp. | System and method for an injection using a syringe needle |
US8177749B2 (en) | 2008-05-20 | 2012-05-15 | Avant Medical Corp. | Cassette for a hidden injection needle |
US9974904B2 (en) | 2008-05-20 | 2018-05-22 | Avant Medical Corp. | Autoinjector system |
TR201802935T4 (tr) * | 2008-09-19 | 2018-03-21 | Pfizer | Stabil sıvı antikor formülasyonu. |
US9393304B2 (en) * | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
KR101841527B1 (ko) | 2010-11-11 | 2018-03-23 | 애브비 바이오테크놀로지 리미티드 | 개선된 고농도 항-TNFα 항체 액체 제형 |
US9173999B2 (en) * | 2011-01-26 | 2015-11-03 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
US9453067B2 (en) * | 2011-04-20 | 2016-09-27 | Sandoz Ag | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
MX358137B (es) | 2011-07-01 | 2018-08-06 | Biogen Idec Inc | Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso. |
WO2013059410A1 (en) * | 2011-10-18 | 2013-04-25 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with xylitol |
WO2013186230A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
US8920374B2 (en) | 2012-07-05 | 2014-12-30 | Unitract Syringe Pty Ltd | Drive control mechanisms and automatic injectors for injectable cartridges |
EA029193B1 (ru) * | 2012-07-09 | 2018-02-28 | Кохерус Байосайенсис, Инк. | Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона |
EP2895188B1 (en) * | 2012-09-11 | 2017-11-15 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
PL2919801T3 (pl) * | 2012-10-26 | 2021-01-25 | Lupin Atlantis Holdings, Sa | Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu |
US9649383B2 (en) | 2012-11-19 | 2017-05-16 | Merck Sharp & Dohme Corp. | Liquid formulations for TNFR:Fc fusion proteins |
KR101419884B1 (ko) * | 2012-11-27 | 2014-07-16 | (주)알테오젠 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
EP2938323A2 (en) | 2012-12-28 | 2015-11-04 | Abbott Cardiovascular Systems, Inc. | Therapeutic compositions comprising antibodies |
TWI580451B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法 |
CA2904661C (en) | 2013-03-15 | 2022-03-15 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
BR112015027764A2 (pt) | 2013-05-02 | 2017-08-29 | Mabxience S A | Formulações alternativas para os polipeptídeos de fusão de tnfr: fc |
MX2016004605A (es) * | 2013-10-24 | 2016-11-14 | Astrazeneca Ab | Formulaciones de anticuerpos estables acuosas. |
CA2930227C (en) * | 2013-11-29 | 2021-09-28 | Ares Trading S.A. | A liquid formulation of a fusion protein comprising tnfr and fc region |
ES2733298T3 (es) | 2014-07-18 | 2019-11-28 | Sandoz Ag | Cuantificación de TNFR2:Fc plegado erróneamente |
AU2015308670B2 (en) | 2014-08-28 | 2020-04-30 | Unitract Syringe Pty Ltd | Sensor systems for drug delivery devices |
DK3185934T3 (en) | 2014-08-28 | 2018-10-01 | Unl Holdings Llc | SKIN SENSORS FOR PHARMACEUTICAL ADMINISTRATION DEVICES |
EP3236990B1 (en) | 2014-12-22 | 2020-09-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
US20180079796A1 (en) | 2015-03-13 | 2018-03-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
US9763976B1 (en) | 2016-08-02 | 2017-09-19 | Zo Skin Health, Inc. | Composition and method for treating skin conditions |
JP6884858B2 (ja) | 2016-10-21 | 2021-06-09 | アムジエン・インコーポレーテツド | 医薬製剤及びその製造方法 |
-
2017
- 2017-10-19 JP JP2019520794A patent/JP6884858B2/ja active Active
- 2017-10-19 CN CN201780072322.9A patent/CN109982685B/zh active Active
- 2017-10-19 EP EP17862991.1A patent/EP3528787A4/en active Pending
- 2017-10-19 KR KR1020217042112A patent/KR102413592B1/ko active IP Right Grant
- 2017-10-19 AU AU2017345490A patent/AU2017345490B2/en active Active
- 2017-10-19 CN CN202210152416.XA patent/CN114917185B/zh active Active
- 2017-10-19 SG SG11201903521XA patent/SG11201903521XA/en unknown
- 2017-10-19 EA EA201990998A patent/EA201990998A1/ru unknown
- 2017-10-19 BR BR112019007858A patent/BR112019007858A2/pt active Search and Examination
- 2017-10-19 KR KR1020197014130A patent/KR102446838B1/ko active IP Right Grant
- 2017-10-19 MX MX2019004580A patent/MX2019004580A/es unknown
- 2017-10-19 CA CA3040899A patent/CA3040899A1/en not_active Abandoned
- 2017-10-19 WO PCT/US2017/057472 patent/WO2018075818A1/en active Application Filing
- 2017-10-19 US US15/788,762 patent/US20180110856A1/en not_active Abandoned
-
2018
- 2018-04-20 US US15/958,261 patent/US10307483B2/en active Active
- 2018-09-27 US US16/144,120 patent/US11491223B2/en active Active
-
2019
- 2019-04-17 CL CL2019001053A patent/CL2019001053A1/es unknown
- 2019-04-18 IL IL266132A patent/IL266132B/en unknown
-
2021
- 2021-05-11 JP JP2021080160A patent/JP7402195B2/ja active Active
-
2022
- 2022-09-16 US US17/933,055 patent/US20230080571A1/en active Pending
-
2023
- 2023-10-19 JP JP2023180119A patent/JP2024010026A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2024010026A5 (ja) | ||
RU2013151303A (ru) | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc | |
JP2022130627A5 (ja) | ||
US7049283B2 (en) | Pharmaceutical compositions for the oral delivery of pharmacologically active agents | |
ES2633574T3 (es) | Formulaciones de antagonistas de VEGF | |
JP2009524595A5 (ja) | ||
JP2011525128A5 (ja) | ||
WO2008145323A1 (en) | Pharmaceutical formulation for interferons | |
CN1523997A (zh) | 稳定的白介素2 | |
JP2014518276A5 (ja) | ||
JP2011502968A5 (ja) | ||
JP2007526317A5 (ja) | ||
US20170281774A1 (en) | Linaclotide compositions | |
AU2009312235B2 (en) | Aqueous composition containing follicle-stimulating hormone | |
US8975227B2 (en) | Intraoral dosage forms of glucagon | |
JP2020536072A5 (ja) | ||
US20230149521A1 (en) | Methods of treating viral infections using arginase | |
ES2349410T3 (es) | Formulación farmacéutica de agente de leucotrieno b4 (ltb4) estabilizado. | |
WO2015068101A1 (en) | Papillomavirus vaccine formulations | |
TWI838584B (zh) | 包含溶栓寡肽-四氫異喹啉綴合物的藥物組合物及凍乾藥物組合物 | |
CN114206319B (zh) | 用于治疗hbv的药物组合物 | |
US20240148820A1 (en) | Anti-viral peptides and compositions and methods of use thereof | |
US20220183993A1 (en) | Thermostable quick-disolving thin film | |
US20240182528A1 (en) | Modified chimeric coronavirus spike protein for enhancement of viral titers | |
RU2021107534A (ru) | Составы, содержащие антитела |